Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

on behalf of the ACMG Professional Practice and Guidelines Committee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: The purpose of this document is to provide updated guidance for the genetic evaluation of cardiomyopathy and for an approach to manage secondary findings from cardiomyopathy genes. The genetic bases of the primary cardiomyopathies (dilated, hypertrophic, arrhythmogenic right ventricular, and restrictive) have been established, and each is medically actionable; in most cases established treatments or interventions are available to improve survival, reduce morbidity, and enhance quality of life. Methods: A writing group of cardiologists and genetics professionals updated guidance, first published in 2009 for the Heart Failure Society of America (HFSA), in a collaboration with the American College of Medical Genetics and Genomics (ACMG). Each recommendation was assigned to teams of individuals by expertise, literature was reviewed, and recommendations were decided by consensus of the writing group. Recommendations for family history, phenotype screening of at-risk family members, referral to expert centers as needed, genetic counseling, and cardiovascular therapies, informed in part by phenotype, are presented in the HFSA document. Results: A genetic evaluation of cardiomyopathy is indicated with a cardiomyopathy diagnosis, which includes genetic testing. Guidance is also provided for clinical approaches to secondary findings from cardiomyopathy genes. This is relevant as cardiomyopathy is the phenotype associated with 27% of the genes on the ACMG list for return of secondary findings. Recommendations herein are considered expert opinion per current ACMG policy as no systematic approach to literature review was conducted. Conclusion: Genetic testing is indicated for cardiomyopathy to assist in patient care and management of at-risk family members.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalGenetics in Medicine
DOIs
StateAccepted/In press - Jun 14 2018

Fingerprint

Genomics
Cardiomyopathies
Medical Genetics
Genetic Testing
Phenotype
Patient Care Management
Genes
Genetic Counseling
Expert Testimony
Consensus
Referral and Consultation
Heart Failure
Quality of Life
Morbidity
Therapeutics

Keywords

  • Cardiomyopathy
  • Genetic analysis
  • Genetics
  • Practice resource
  • Secondary findings

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Genetic evaluation of cardiomyopathy : a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). / on behalf of the ACMG Professional Practice and Guidelines Committee.

In: Genetics in Medicine, 14.06.2018, p. 1-11.

Research output: Contribution to journalArticle

@article{01b52cf2cba74b15985db1917de2b14f,
title = "Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)",
abstract = "Purpose: The purpose of this document is to provide updated guidance for the genetic evaluation of cardiomyopathy and for an approach to manage secondary findings from cardiomyopathy genes. The genetic bases of the primary cardiomyopathies (dilated, hypertrophic, arrhythmogenic right ventricular, and restrictive) have been established, and each is medically actionable; in most cases established treatments or interventions are available to improve survival, reduce morbidity, and enhance quality of life. Methods: A writing group of cardiologists and genetics professionals updated guidance, first published in 2009 for the Heart Failure Society of America (HFSA), in a collaboration with the American College of Medical Genetics and Genomics (ACMG). Each recommendation was assigned to teams of individuals by expertise, literature was reviewed, and recommendations were decided by consensus of the writing group. Recommendations for family history, phenotype screening of at-risk family members, referral to expert centers as needed, genetic counseling, and cardiovascular therapies, informed in part by phenotype, are presented in the HFSA document. Results: A genetic evaluation of cardiomyopathy is indicated with a cardiomyopathy diagnosis, which includes genetic testing. Guidance is also provided for clinical approaches to secondary findings from cardiomyopathy genes. This is relevant as cardiomyopathy is the phenotype associated with 27{\%} of the genes on the ACMG list for return of secondary findings. Recommendations herein are considered expert opinion per current ACMG policy as no systematic approach to literature review was conducted. Conclusion: Genetic testing is indicated for cardiomyopathy to assist in patient care and management of at-risk family members.",
keywords = "Cardiomyopathy, Genetic analysis, Genetics, Practice resource, Secondary findings",
author = "{on behalf of the ACMG Professional Practice and Guidelines Committee} and Hershberger, {Ray E.} and Givertz, {M. M.} and Ho, {Carolyn Y.} and Judge, {Daniel P.} and Kantor, {P. F.} and McBride, {Kim L.} and Ana Morales and Taylor, {Matthew R.G.} and Matteo Vatta and Stephanie Ware",
year = "2018",
month = "6",
day = "14",
doi = "10.1038/s41436-018-0039-z",
language = "English (US)",
pages = "1--11",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Genetic evaluation of cardiomyopathy

T2 - a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

AU - on behalf of the ACMG Professional Practice and Guidelines Committee

AU - Hershberger, Ray E.

AU - Givertz, M. M.

AU - Ho, Carolyn Y.

AU - Judge, Daniel P.

AU - Kantor, P. F.

AU - McBride, Kim L.

AU - Morales, Ana

AU - Taylor, Matthew R.G.

AU - Vatta, Matteo

AU - Ware, Stephanie

PY - 2018/6/14

Y1 - 2018/6/14

N2 - Purpose: The purpose of this document is to provide updated guidance for the genetic evaluation of cardiomyopathy and for an approach to manage secondary findings from cardiomyopathy genes. The genetic bases of the primary cardiomyopathies (dilated, hypertrophic, arrhythmogenic right ventricular, and restrictive) have been established, and each is medically actionable; in most cases established treatments or interventions are available to improve survival, reduce morbidity, and enhance quality of life. Methods: A writing group of cardiologists and genetics professionals updated guidance, first published in 2009 for the Heart Failure Society of America (HFSA), in a collaboration with the American College of Medical Genetics and Genomics (ACMG). Each recommendation was assigned to teams of individuals by expertise, literature was reviewed, and recommendations were decided by consensus of the writing group. Recommendations for family history, phenotype screening of at-risk family members, referral to expert centers as needed, genetic counseling, and cardiovascular therapies, informed in part by phenotype, are presented in the HFSA document. Results: A genetic evaluation of cardiomyopathy is indicated with a cardiomyopathy diagnosis, which includes genetic testing. Guidance is also provided for clinical approaches to secondary findings from cardiomyopathy genes. This is relevant as cardiomyopathy is the phenotype associated with 27% of the genes on the ACMG list for return of secondary findings. Recommendations herein are considered expert opinion per current ACMG policy as no systematic approach to literature review was conducted. Conclusion: Genetic testing is indicated for cardiomyopathy to assist in patient care and management of at-risk family members.

AB - Purpose: The purpose of this document is to provide updated guidance for the genetic evaluation of cardiomyopathy and for an approach to manage secondary findings from cardiomyopathy genes. The genetic bases of the primary cardiomyopathies (dilated, hypertrophic, arrhythmogenic right ventricular, and restrictive) have been established, and each is medically actionable; in most cases established treatments or interventions are available to improve survival, reduce morbidity, and enhance quality of life. Methods: A writing group of cardiologists and genetics professionals updated guidance, first published in 2009 for the Heart Failure Society of America (HFSA), in a collaboration with the American College of Medical Genetics and Genomics (ACMG). Each recommendation was assigned to teams of individuals by expertise, literature was reviewed, and recommendations were decided by consensus of the writing group. Recommendations for family history, phenotype screening of at-risk family members, referral to expert centers as needed, genetic counseling, and cardiovascular therapies, informed in part by phenotype, are presented in the HFSA document. Results: A genetic evaluation of cardiomyopathy is indicated with a cardiomyopathy diagnosis, which includes genetic testing. Guidance is also provided for clinical approaches to secondary findings from cardiomyopathy genes. This is relevant as cardiomyopathy is the phenotype associated with 27% of the genes on the ACMG list for return of secondary findings. Recommendations herein are considered expert opinion per current ACMG policy as no systematic approach to literature review was conducted. Conclusion: Genetic testing is indicated for cardiomyopathy to assist in patient care and management of at-risk family members.

KW - Cardiomyopathy

KW - Genetic analysis

KW - Genetics

KW - Practice resource

KW - Secondary findings

UR - http://www.scopus.com/inward/record.url?scp=85048581688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048581688&partnerID=8YFLogxK

U2 - 10.1038/s41436-018-0039-z

DO - 10.1038/s41436-018-0039-z

M3 - Article

C2 - 29904160

AN - SCOPUS:85048581688

SP - 1

EP - 11

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

ER -